0000000001316851

AUTHOR

Luis Garcia

showing 6 related works from this author

Recent results on heavy-ion induced reactions of interest for neutrinoless double beta decay at INFN-LNS

2019

Abstract The NUMEN project aims at accessing experimentally driven information on Nuclear Matrix Elements (NME) involved in the half-life of the neutrinoless double beta decay (0νββ). In this view measurements of Heavy Ion (HI) induced Double Charge Exchange (DCE) reaction cross sections are performed with high-accuracy. In particular, the (18O,18Ne) and (20Ne,20O) reactions are used as tools for β+β+ and β-β- decays, respectively. In the experiments, performed at INFN - Laboratory Nazionali del Sud (LNS) in Catania, the beams are accelerated by the Superconducting Cyclotron (CS) and the reaction ejectiles are detected the MAGNEX magnetic spectrometer. The measured cross sections are challe…

Historyexperimental methodsheavy ion: scatteringQC1-999heavy ion: charge exchange[PHYS.NEXP]Physics [physics]/Nuclear Experiment [nucl-ex]hiukkasfysiikka7. Clean energy01 natural sciencesEducationNuclear physicsdouble-beta decay: (0neutrino)Double beta decay0103 physical sciencesneutrino: mass010306 general physicsnucleus: semileptonic decayPhysics010308 nuclear & particles physicsPhysicsparticle: MajoranaNuclear structurecross section: measuredSpecial classmagnetic spectrometercharge exchangedetector: upgradeneon: nuclideComputer Science Applicationsheavy ion induced double charge exchange reactionsneutrino: MajoranaHeavy ionenergy resolution: highydinfysiikkaCharge exchangeexperimental resultsEPJ Web of Conferences
researchProduct

Combined effect of AAV-U7-induced dystrophin exon skipping and soluble activin Type IIB receptor in mdx mice.

2012

Adeno-associated virus (AAV)-U7-mediated skipping of dystrophin-exon-23 restores dystrophin expression and muscle function in the mdx mouse model of Duchenne muscular dystrophy. Soluble activin receptor IIB (sActRIIB-Fc) inhibits signaling of myostatin and homologous molecules and increases muscle mass and function of wild-type and mdx mice. We hypothesized that combined treatment with AAV-U7 and sActRIIB-Fc may synergistically improve mdx muscle function. Bioactivity of sActRIIB-Fc on skeletal muscle was first demonstrated in wild-type mice. In mdx mice we show that AAV-U7-mediated dystrophin restoration improved specific muscle force and resistance to eccentric contractions when applied a…

musculoskeletal diseasesmdx mousemedicine.medical_specialtycongenital hereditary and neonatal diseases and abnormalitiesDuchenne muscular dystrophyActivin Receptors Type IIGenetic VectorsMyostatinBiologyDystrophin03 medical and health sciencesMice0302 clinical medicineInternal medicineGeneticsmedicineMyocyteAnimalsMuscular dystrophyMuscle SkeletalMolecular Biology030304 developmental biology0303 health sciencesBody WeightSkeletal muscleExonsGenetic TherapyDependovirusMuscular Dystrophy Animalmedicine.diseasemusculoskeletal system3. Good healthMice Inbred C57BLEndocrinologymedicine.anatomical_structureImmunologybiology.proteinMice Inbred mdxMolecular MedicineITGA7Dystrophin030217 neurology & neurosurgeryMuscle ContractionHuman gene therapy
researchProduct

40(th) EASD Annual Meeting of the European Association for the Study of Diabetes : Munich, Germany, 5-9 September 2004

2004

0303 health sciencesmedicine.medical_specialtybusiness.industryEASDEndocrinology Diabetes and MetabolismHuman physiologymedicine.disease03 medical and health sciences0302 clinical medicineDiabetes mellitusFamily medicineInternal MedicineMedicinebusiness030217 neurology & neurosurgery030304 developmental biology
researchProduct

SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study

2021

SARS-CoV-2 has been associated with an increased rate of venous thromboembolism in critically ill patients. Since surgical patients are already at higher risk of venous thromboembolism than general populations, this study aimed to determine if patients with peri-operative or prior SARS-CoV-2 were at further increased risk of venous thromboembolism. We conducted a planned sub-study and analysis from an international, multicentre, prospective cohort study of elective and emergency patients undergoing surgery during October 2020. Patients from all surgical specialties were included. The primary outcome measure was venous thromboembolism (pulmonary embolism or deep vein thrombosis) within 30 da…

Malepulmonary embolismInternationalitySettore MED/18 - CHIRURGIA GENERALEDeep veinVascular damage Radboud Institute for Health Sciences [Radboudumc 16]infectious diseasesCardiovascularSARS‐CoV‐2surgeryCOVID-19 ; SARS-CoV-2 ; deep vein thrombosis ; pulmonary embolism ; venous thromboembolismCohort StudiesPostoperative ComplicationsAnesthesiologyMedicine and Health SciencesProspective Studies610 Medicine & healthProspective cohort studyLung11 Medical and Health SciencesConfoundingHematologyMiddle AgedThrombosis17 Psychology and Cognitive SciencesCOVID-19; deep vein thrombosis; pulmonary embolism; SARS-CoV-2; venous thromboembolismPulmonary embolismCOVID-19; SARS-CoV-2; deep vein thrombosis; pulmonary embolism; venous thromboembolism.medicine.anatomical_structureCohortCOVID-19/complicationsPostoperative Complications/etiologyOriginal ArticleFemalePatient SafetyLife Sciences & BiomedicineCOVID-19; SARS-CoV-2; deep vein thrombosis; pulmonary embolism; venous thromboembolismHumanAdultmedicine.medical_specialtyAdolescentClinical Sciencesvenous thromboembolism610 Medicine & healthGlobalSurg CollaborativeVenous Thromboembolism/etiologydeep vein thrombosisNOCOVIDSurg CollaborativeYoung AdultMedicine General & InternalAge DistributionClinical ResearchCOVID‐19General & Internal MedicinemedicineHumansSex DistributionAgedScience & Technologybusiness.industrySARS-CoV-2PreventionNeurosciencesdeep vein thrombosiCOVID-19PneumoniaOdds ratioOriginal Articlesmedicine.diseaseSurgeryReconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10]Prospective StudieGood Health and Well BeingAnesthesiology and Pain MedicineHuman medicinePostoperative ComplicationCohort StudiebusinessVenous thromboembolism[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial …

2015

BACKGROUND: Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagon-like peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated.METHODS: ELIXA (www.clinicaltrials.gov no. NCT01147250) is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study of lixisenatide in patients with T2DM and a recent ACS event. The primary aim is to evaluate the effects of lixisenatide on CV morbidity and mortality in a population …

Malemedicine.medical_specialtyAcute coronary syndromePopulationLIXisenatide610 Medicine & healthHypoglycemiaPlacebop38 Mitogen-Activated Protein Kinases11171 Cardiocentro Ticino2705 Cardiology and Cardiovascular Medicinelaw.inventionSettore MED/13 - EndocrinologiaAcute Coronary Syndrome; Aged; Cardiovascular Diseases; Double-Blind Method; Female; Glucagon-Like Peptide 1; Humans; Male; Middle Aged; Peptides; Placebos; Protein Kinase Inhibitors; Research Design; p38 Mitogen-Activated Protein Kinases; Cardiology and Cardiovascular MedicinePlacebosLixisenatidechemistry.chemical_compoundRandomized controlled trialDouble-Blind MethodlawGlucagon-Like Peptide 1Internal medicineJournal ArticlemedicineHumansComparative StudyMyocardial infarctionAcute Coronary SyndromeeducationProtein Kinase InhibitorsAgededucation.field_of_studybusiness.industryUnstable anginaResearch Support Non-U.S. Gov'tta3121Middle Agedmedicine.diseaseSurgeryMulticenter StudychemistryCardiovascular DiseasesResearch DesignRandomized Controlled TrialCardiologyFemaleCardiology and Cardiovascular MedicinebusinessPeptides
researchProduct

CCDC 924213: Experimental Crystal Structure Determination

2013

Related Article: Gregorio Sanchez, Joaquin Garcia, Malva Liu, Luis Garcia, Jose Perez, Eduardo Perez,Jose L. Serrano|2013|J.Coord.Chem.|66|2919|doi:10.1080/00958972.2013.817572

Space GroupCrystallography(2-(45-Dihydro-13-oxazol-2-yl)phenyl)-(2-(diphenylphosphino)benzaldehyde)-palladium(ii) trifluoromethanesulfonateCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct